Data presented at AACR Annual Meeting
2019
- In vivo study conducted alone or in
collaboration with The University of Texas MD Anderson Cancer
Center demonstrated:
- NBTXR3 in combination with a PD-1 inhibitor enhanced an
abscopal effect in both sensitive and PD-1-inhibitor-resistant
lung cancer models
- NBTXR3 in combination with a PD-1 inhibitor showed
significant reduction of metastatic load in PD-1-inhibitor-
sensitive lung cancer models
- NBTXR3 in combination with a CTLA-4 inhibitor enhanced
an abscopal effect in colorectal cancer models
- Data presented by the Weill Cornell Medical College
showed that NBTXR3 mode of action induced interferon (IFN-β)
expression in breast cancer cell line
- Altogether, the data presented support the ongoing
clinical development plan for combinations of NBTXR3 with
radiotherapy and immuno-oncology (IO) agents in multiple
indications including lung- and head and neck cancers
Paris, France; Cambridge, Massachusetts
(USA); April 2, 2019 – NANOBIOTIX (Euronext: NANO – ISIN:
FR0011341205 – the ‘‘Company’’) a
clinical-stage nanomedicine company pioneering new approaches to
the treatment of cancer, today announced preclinical data from
studies currently being conducted under its collaborations with The
University of Texas MD Anderson Cancer Center and the Weill Cornell
Medical College. These results were presented during two poster
sessions at the American Association for Cancer Research (AACR)
Annual Meeting 2019, currently taking place in Atlanta, Georgia,
USA from March 29 to April 3, 2019.
This initial pre-clinical set of
NBTXR3/radiotherapy/IO combination data provides further insights
into the immune-activation caused by NBTXR3 and strengthens the
understanding of the potential systemic effects provided by NBTXR3.
Thus, the Company believes it formulates sound rationale to support
its clinical development program investigating the combination of
NBTXR3, radiotherapy and IO agents.
Enhancement of anti-PD-1 and anti-CTLA4
efficacy by NBTXR3 nanoparticles exposed to radiotherapy Poster
#3225Yun Hu1, Ping Zhang2, Audrey Darmon2, Maria Angelica
Cortez1, Sébastien Paris2, James Welsh11MD Anderson Cancer Center,
Houston, TX; 2Nanobiotix, Paris, France
In both 344SQ_P (sensitive to
anti-PD-1 treatment) and 344SQ_R (resistant to
anti-PD-1 treatment) lung cancer models, the combination of
anti-PD-1 + radiotherapy + NBTXR3 demonstrated both better control
of the treated tumor and the distant untreated tumor as well as
increased survival when compared to monotherapy. Importantly, it
was observed that this combination decreased spontaneous lung
metastasis formation in the anti-PD-1 sensitive 344SQ_P model.
For the CT26.WT colon carcinoma
model, as previously reported, NBTXR3 activated by radiotherapy
generated an abscopal effect. It was observed that administration
of anti-CTLA4 monotherapy demonstrated control of both treated and
distant untreated tumors, potentially indicating that the
CT26.WT was sensitive to a checkpoint inhibitor.
The addition of radiotherapy to anti-CTLA4 only improved the tumor
control modestly compared to anti-CTLA4 alone. In contrast, the
combination of anti-CTLA4 + radiotherapy + NBTXR3 in this trial
showed the best control of the treated and distant untreated
tumors, then any single agent or doublet combination.
NBTXR3
Potentiates Cancer-Cell Intrinsic Interferon beta Response to
Radiotherapy Poster #3366Maria Esperanza Rodriguez-Ruiz1,
Karsten A Pilones1, Camille Daviaud1, Jeffrey Kraynak1, Audrey
Darmon2, Sébastien Paris2 and Sandra Demaria1 1Department of
Radiation Oncology, Weill Cornell Medicine, New York, USA;
2Nanobiotix, Paris, France
Data suggests that NBTXR3 enhances the
effectiveness of radiation and improves tumor immunogenicity in
murine breast cancer cell lines, via the induction of type-I
interferon (IFN-I). In the study, NBTXR3 activated by radiotherapy
amplified cancer cell intrinsic IFN-I response and showed a
significant improvement in tumor control compared to radiotherapy
alone with complete durable regression of tumors.
-Ends-
About NBTXR3
NBTXR3 is a first-in-class product candidate
designed to destroy tumors and metastasis when activated by
radiotherapy.
NBTXR3 has a high degree of biocompatibility and
requires one single administration before the whole radiotherapy
treatment. Nanobiotix believes NBTXR3 has the ability to fit into
current worldwide standards of radiation care.
Nanobiotix’s broad clinical program includes
seven clinical trials. In June 2018, Nanobiotix established human
proof of concept for this first-in-class product candidate in its
soft tissue sarcoma (STS) Phase III clinical trial.
NBTXR3 is actively being studied in head and
neck cancer with locally advanced squamous cell carcinoma of the
oral cavity or oropharynx in elderly and frail patients who are
unable to receive chemotherapy or cetuximab and have very limited
therapeutic options. Promising results from these clinical studies
have been observed from the ongoing Phase I/II trial regarding the
local control of tumors.
Nanobiotix is also running an immuno-oncology
development program. In the United States, Nanobiotix has received
approval from the U.S. Food and Drug Administration to launch a
clinical study of NBTXR3 activated by radiotherapy in combination
with anti-PD1 antibodies in lung, and head and neck cancer patients
(head and neck squamous cell carcinoma and non-small cell lung
cancer).
The other ongoing NBTXR3 trials are treating
patients with liver cancers (hepatocellular carcinoma and liver
metastasis), locally advanced or unresectable rectal cancer in
combination with chemotherapy, head and neck cancer in combination
with concurrent chemotherapy, and prostate adenocarcinoma.
The first market authorization process (CE
Marking) for the STS indication is ongoing in Europe.
About
NANOBIOTIX:
Incorporated in 2003, Nanobiotix is a leading,
clinical-stage nanomedicine company pioneering new approaches to
significantly change patient outcomes by bringing nanophysics to
the heart of the cell.
The Nanobiotix philosophy is rooted in designing
pioneering, physical-based approaches to bring highly effective and
generalized solutions to address unmet medical needs and
challenges.
Nanobiotix’s first-in-class, proprietary lead
technology, NBTXR3, aims to expand radiotherapy benefits for
millions of cancer patients. Nanobiotix’s Immuno-Oncology program
has the potential to bring a new dimension to cancer
immunotherapies.
Nanobiotix is listed on the regulated market of
Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg:
NANO: FP). The Company’s headquarters are in Paris, France, with a
U.S. affiliate in Cambridge, MA, and European affiliates in Spain
and Germany.
Contacts
Nanobiotix |
|
Communications Department+33 (0)1 40 26 07
55+1 (617) 852-4835contact@nanobiotix.com |
Investor Relations
Department +33 (0)1 79 97 29 99+1 (646) 241-4400
investors@nanobiotix.com |
|
Media Relations |
|
France - Springbok ConsultantsMarina
Rosoff+33 (0)6 71 58 00 34marina@springbok.fr |
|
US – RooneyPartners Marion Janic
+1 (212) 223-4017mjanic@rooneyco.com |
|
|
DisclaimerThis press release
contains certain forward-looking statements concerning Nanobiotix
and its business. Such forward-looking statements are based on
assumptions that Nanobiotix considers to be reasonable. However,
there can be no assurance that the estimates contained in such
forward-looking statements will be verified, which estimates are
subject to numerous risks including the risks set forth in the
reference document of Nanobiotix filed with the French Financial
Markets Authority (Autorité des Marchés Financiers) under number
D.17-0470 on April 28, 2017 as well as in its 2017 annual financial
report filed with the French Financial Markets Authority on March
29, 2018 (a copy of which is available on www.nanobiotix.com) and
to the development of economic conditions, financial markets and
the markets in which Nanobiotix operates. The forward-looking
statements contained in this press release are also subject to
risks not yet known to Nanobiotix or not currently considered
material by Nanobiotix. The occurrence of all or part of such risks
could cause actual results, financial conditions, performance or
achievements of Nanobiotix to be materially different from such
forward-looking statements. This press release and the information
that it contains do not constitute an offer to sell or subscribe
for, or a solicitation of an offer to purchase or subscribe for,
Nanobiotix shares in any country. At the moment, NBTXR3 does not
bear a CE mark and the Company is not permitted to be place NBTXR3
on the market or put into service until it has obtained a CE
mark.
- 2019_Nanobiotix_AACR Results Announcement_VF_02042019
Nanobiotix (EU:NANO)
Historical Stock Chart
From May 2024 to Jun 2024
Nanobiotix (EU:NANO)
Historical Stock Chart
From Jun 2023 to Jun 2024